investor harm

Ultragenyx Pharmaceutical faces securities fraud lawsuit alleging misrepresentations of setrusumab trial results and inadequate risk disclosures to investors.

Class action lawsuit filed against $MNDY alleging materially false statements about revenue expansion and growth prospects from September 2025 to February 2026.

Class action filed against $AMC over alleged securities violations regarding APE preferred equity units. Investors claim misleading disclosures about distribution rights after conversion.

Class action lawsuit filed against Coty Inc. alleging executives made false statements about growth and profitability during November 2025-February 2026 period.

Class action lawsuit filed against $TCOM for alleged securities fraud involving undisclosed monopolistic business risks. Lead plaintiff deadline set for May 11, 2026.

Alight faces class action lawsuit alleging executives made false statements about growth prospects and capital returns during 15-month period from November 2024 to February 2026.

Class action lawsuit filed against Lufax Holding Ltd alleging securities fraud and false financial statements. Coverage period spans April 2023 to January 2025.

Bronstein, Gewirtz & Grossman filed class action against Super Micro Computer alleging undisclosed China sales violating export controls. Shareholders purchased between April 30, 2024 and March 19, 2026 may join; lead plaintiff deadline May 26, 2026.

Class action lawsuit filed against $GARTNER alleging executives made false statements about contract value, revenue, and consulting segment performance between Feb 2025-Feb 2026.

Lawsuit filed against Corcept Therapeutics alleging false statements about relacorilant drug trials and FDA communications, covering October 2024-December 2025 investor purchases.

Class action lawsuit filed against Nektar Therapeutics alleging executives made false statements about REZOLVE-AA trial enrollment protocols, potentially overstating trial integrity and results.

Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 trials ORBIT and COSMIC; investors in $MREO securities from June 2023-December 2025 urged to act by April 6, 2026 deadline.

Class action lawsuit filed against $SNOW alleges securities fraud over nondisclosure of product efficiency changes impacting consumption and revenues during June 2023-February 2024 period.

Class action lawsuit filed against $HCA alleging materially false statements regarding due diligence, loan origination, and portfolio valuation between May 2025 and February 2026.

Class action lawsuit filed against $ATARAWITH alleging executives made false statements about manufacturing issues and ALLELE study deficiencies that could block FDA approval of tabelecleucel.

Class action lawsuit alleges $PSIX made false statements about data center demand and understated manufacturing costs, covering May 2025-March 2026 investors.

Class action lawsuit filed against Kyndryl for alleged false financial statements and internal control failures during August 2024-February 2026 period.

Class action lawsuit filed against PayPal alleging executives made false statements about revenue projections and 2027 targets under CEO James Chriss.

Class action lawsuit filed against $ENPH alleging overstatement of inventory management and tax credit mitigation capabilities. Lead plaintiff deadline set for April 20, 2026.

Class action lawsuit filed against $AMC alleging securities fraud over APE preferred equity units excluded from special dividend after conversion to common stock.